A Crossover Study on the Glucose Metabolism Between Treatment With Olanzapine and Risperidone in Schizophrenic Patients

Experimental and Clinical Psychopharmacology

Volumn 18, Issue 5, 2010, Pages 445-450

  Sato, Yasushi ^a   Yasui Furukori, Norio ^a   Furukori, Hanako ^a   Saito, Manabu ^a   Nakagami, Taku ^a   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Crossover study; Glucose metabolisms; OGTT; Olanzapine; Risperidone

Indexed keywords

GLUCOSE; INSULIN; OLANZAPINE; RISPERIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; JAPANESE; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CROSS-OVER STUDIES; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA;

EID: 77958127720     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0020751     Document Type: Article

References (46)

1. Ader M., Garvey T., Phillips L., Nemeroff C., Gharabawi G., Mahmoud R., Greenspan A., et al. Ethnic heterogeneity in glucoregulation function during treatment with atypical antipsychotics in patients with schizophrenia. Journal of Psychiatric Research 2008, 42:1076-1085.
2. Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., Kabir M., et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005, 54:862-871.
3. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 1999, 156:1686-1696.
4. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601. American Diabetes Association.
5. Baptista T. Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatrica Scandinavica 1999, 100:3-16.
6. Bock G., Dalla, Man C., Campioni M., Chittilapilly E., Basu R., Toffolo G., et al. Pathogenesis of pre-diabetes: Mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006, 55:3536-3549.
7. Dibben C.R., Kalavalapalli S.S., Linnington H.E., Hynes F.A., Dinneen S.F., Adler A.I., Mckenna P.J. Diabetes associated with atypical antipsychotic treatment may be Severe but reversible: Case report. International Journal of Psychiatry in Medicine 2005, 35:307-311.
8. Dwyer D.S., Lu X.H., Bradley R.J. Cytoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Research 2003, 971:31-39.
9. Fedele D., Comi G., Coscelli C., Cucinotta D., Feldman E.L., Ghirlanda G., Greene D.A., et al. A multicenter study on the prevalence of diabetic neuropathy in Italy: Italian Diabetic Neuropathy Committee. Diabetes Care 1997, 20:836-843.
10. Gabbay K.H., O'Sullivan J.B. The sorbitol pathway: Enzyme location and content in normal and diabetic nerve and cord. Diabetes 1968, 17:239-243.
11. Hansen T., Drivshoem T., Urhammer S., Palacios R., Volund A., Borch-Johnson K., Pedersen O. The BIGTT test: A novel test for simultaneous measurement of pancreatic B-Cell function, insulin sensitivity and glucose tolerance. Diabetes Care 2007, 30:257-262.
12. Harris E.C., Barraclough B. Excess mortality of mental disorder. British Journal of Psychiatry 1998, 173:11-53.
13. Henderson D.C. Schizophrenia and comorbid metabolic disorders. Journal of Clinical Psychiatry 2005, 66(Suppl. 6):11-20.
14. Henderson D.C., Cagliero E., Copeland P.M., Borba C.P., Evins E., Hayden D., Weber M.T., et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of General Psychiatry 2005, 62:19-28.
15. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., Goff D.C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities. A five-year naturalistic study. American Journal of Psychiatry 2000, 157:975-981.
16. Henderson D.C., Nguyen D.D., Copeland P.M., Hayden D.L., Borba C.P., Louie P.M., Freudenreich O., et al. Clozapine, diabetes mellitus, hyperlipidemia and cardiovascular risks and mortality:results of a 10-year naturalistic study. Journal of Clinical Psychiatry 2005, 66:1116-1121.
17. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W.S., Treadway J.L., Gibbs E.M., et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005, 54:1552-1558.
18. Joukamaa M., Heliövaara M., Knekt P., Aromaa A., Raitasalo R., Lehtinen V. Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry 2006, 188:122-127.
19. Kabinoff G.S., Toalson P.A., Healey K.M., Mcguire H.C., Hay D.P. Metabolic issues with atypical antipsychotics in primary care: Dispelling the myths. Journal of Clinical Psychiatry 2003, 5:6-14.
20. Kane J.M., Barrett E.J., Casey D.E., Correll C.U., Gelenberg A.J., Klein S., Newcomer J.W. Metabolic effects of treatment with atypical antipsychotics. Journal of Clinical Psychiatry 2004, 65:1447-1455.
21. Koller E.A., Cross J.T., Doraiswamy P.M., Schneider B.S. Risperidone-associated diabetes mellitus: A pharmacovigilance study. Pharmacotherapy 2003, 23:735-744.
22. Koller E.A., Doraiswamy P.M. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002, 22:841-852.
23. Lafayette J.M., Piri W.F., Henderson D.C. Low-dose clozapine and diabetes ketoacidosis. Psychosomatics 2003, 44:249-252.
24. Lean M.E., Pajonk F.G. Patients on atypical antipsychotic drugs another high-risk group for type 2 diabetes. Diabetes Care 2003, 26:1597-1605.
25. Lee E., Leung C.M., Wong E. Atypical antipsychotics and weight gain in Chinese patients: A comparison of olanzapine and risperidone. Journal of Clinical Psychiatry 2004, 65:864-866.
26. Lieberman J.A., Stroup T.S., Mcevoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005, 353:1209-1223.
27. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., Kane J.M., et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 2004, 161:1334-1349.
28. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Davis J.M., Kane J.M., Lieberman J., et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophrenia Bulletin 2002, 28:5-16.
29. Matsuda M., Defronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462-1470.
30. Meyer C., Pimenta W., Woerle H.J., Van Haeften T., Szoke E., Mitrakou A., Gerich J. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 2006, 29:1909-1914.
31. Meyer J.M. A Retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: Metabolic outcomes after 1 year. Journal of Clinical Psychiatry 2002, 63:425-433.
32. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. Journal of Clinical Psychiatry 2004, 68(Suppl. 1):20-27.
33. Newcomer J.W. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. Journal of Clinical Psychiatry 2004, 65(Suppl. 18):36-46.
34. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormality in glucose regulation during antipsychotic treatment of schizophrenia. Acta General Psychiatry 2002, 59:337-345.
35. Newcomer J.W., Ratner R., Eriksson J., Emsley R., Meulien D., Miller F., Leonova-Edlund J., et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. Journal of Clinical Psychiatry 2009, 70:487-499.
36. Oates P.J. Polyol pathway and diabetic peripheral neuropathy. International Review of Neurobiology 2002, 50:325-392.
37. Ryan M.C.M., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry 2003, 160:284-289.
38. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry 2002, 159:561-566.
39. Smith R., Lindenmayer J., Davis J., Kelly E., Viviano T., Cornwell J., Hu Q., et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study. Journal of Clinical Psychiatry 2009, 70:1501-1513.
40. Su K.P., Wu P.L., Pariante C.M. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology 2005, 183:383-386.
41. Tripathy D., Tuomi T., Almgren P. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 2004, 27:2204-2210.
42. Vestri H.S., Maianu L., Moellering D.R., Garvey W.T. Atypical antipsychotic drugs directly impair insulin action in adipocytes: Effects on glucose transport, lipogenesis, and antilipolisis. Neuropsychopharmacology 2007, 32:765-772.
43. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., Wirshing W.C. The effects of novel antipsychotics on glucose and lipid levels. Journal of Clinical Psychiatry 2002, 63:856-865.
44. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 2003, 64:663-667.
45. Yasui-Furukori N., Sato Y., Furukori H., Saito M., Nakagami T., Kaneko K. Glucose metabolism in Japanese schizophrenic patients treated with risperidone or olanzapine. Journal of Clinical Psychiatry 2009, 70:95-100.
46. Zhang F., Basinski M.B., Beals J.M., Briggs S.L., Churgay L.M., Clawson D.K., Dimarchi R.D., et al. Crystal structure of the obese protein leptin-E100. Nature 1997, 387:206-209.